血清LDH、β_2-MG在急性白血病中的临床意义

Clinical significance of serum lactic dehydrogenase,β_2-microglobulin in acute leukemia

目的:测定急性白血病(AL)患者血清LDH、β2-MG水平,探讨其对AL患者疗效及预后的价值。方法:对急性白血病患者154例分别采用速率法及放免法测定血清LDH、β2-MG水平。结果:(1)随着外周血白细胞总数的增加,LDH与化疗前外周血白细胞总数呈正相关(r=0.543,P<0.01);LDH与周围血、骨髓原始细胞数无相关性。(2)随着血清LDH、血β2-MG值升高,急性白血病患者的第1次缓解率逐渐下降、半年复发率逐渐上升;(3)急淋患者的LDH水平比急性非淋患者LDH水平高。结论:血清LDH、β2-MG可作为判断急性白血病疗效及预后可靠参考指标;LDH也是反映AL肿瘤负荷的一项可靠指标。

Objective：To determine the serum levels of lactic dehydrogenase （LDH）, β2-microglobulin （β2-MG）, and evaluate its value on the efficacy and prognosis in acute leukemia （AL） patients. Methods： The level of serum LDH with rate method and β2-MG with radioimmunoassay were tested in 154 cases of acute leukemia patients. Results： With gradual increase in serum LDH and β2-MG, first remission rate gradually decreased, and the recurrence rate gradually increased after six months in acute leukemia patients. LDH level in acute lymphoblastic leukemia was higher than that in acute nonlymphocytic leukemia in patients. Conclusion： Serum LDH, β2-MG are regarded as a reliable reference index to judge the efficacy and prognosis in acute leukemia; LDH is also reflected as a reliable indicator of the AL tumor burden.